BioSpace News Archive

Adjuvant Verzenio in combination with endocrine therapy (ET) continued to demonstrate a significant improvement in reducing the risk of recurrence in patients with HR+ HER2-, node-positive, high risk early breast cancer

Meridian Bioscience, Inc. will report fourth quarter and full year 2021 financial results Friday, November 12, 2021 .

Pharnext SA, an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PLEOTHERAPY platform, announces its financial results for first-half of 2021.

Culture Biosciences, a company enabling biotech firms to develop and scale manufacturing processes in the cloud, announced a Series B financing of $80 million led by Northpond Ventures. Synthesis Capital also participated in the round.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), today announced that it has submitted its Type II variation application to the European Medicines Agency (EMA) for IMCIVREE® (setmelanotide) for the treatment of obesity and control of hunger in adult and pediatric patients six years of age and older with Bardet-Biedl syndrome (BBS) or Alström syndrome.

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, October 29, 2021 to discuss its third quarter operating results

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (“Genomma Lab” or “the Company”), today announced that it will report its Third Quarter 2021 results on Wednesday, October 27, 2021 after the Mexican Market (BMV) close.

Arthritis Research Canada scientists have created a new grading scale to measure the severity of osteoarthritis in patients.

MiMedx Group, Inc., an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, announced that it will host a virtual Investor Day on Tuesday, December 7, 2021 beginning at 9:00 a.m. ET.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its third quarter 2021 financial results and provide a corporate update on Thursday, November 4, 2021, after the close of the U.S. financial markets.